For research use only. Not for therapeutic Use.
Dalfopristin（Cat No.:I000465）is a semi-synthetic antibiotic that belongs to the streptogramin class and is typically used in combination with quinupristin to form the drug Synercid. This combination is effective against a range of gram-positive bacteria, including multi-resistant strains like Staphylococcus aureus and Enterococcus faecium. Dalfopristin works by inhibiting bacterial protein synthesis, specifically binding to the 50S ribosomal subunit, which enhances the action of quinupristin. Together, they exhibit a synergistic effect, leading to greater antibacterial efficacy. Dalfopristin’s role in combating resistant infections makes it essential in clinical and antimicrobial research.
| Catalog Number | I000465 |
| CAS Number | 112362-50-2 |
| Molecular Formula | C34H50N4O9S |
| Purity | ≥95% |
| Target | Antibacterial[1] |
| Solubility | DMSO: ≥ 30 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone |
| InChI | InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1 |
| InChIKey | SUYRLXYYZQTJHF-VMBLUXKRSA-N |
| SMILES | CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C |
| Reference | </br>1:Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China. Wang S, Guo Y, Lv J, Qi X, Li D, Chen Z, Zhang X, Wang L, Yu F.BMC Microbiol. 2016 Oct 21;16(1):246. PMID: 27769188 Free PMC Article</br>2:Daptomycin-Vancomycin-Resistant Enterococcus faecium Native Valve Endocarditis: Successfully Treated With Off-Label Quinupristin-Dalfopristin. Hussain K, Ullah S, Tahir H, Alkilani WZ, Naeem M, Vinod NR, Massoud S.J Investig Med High Impact Case Rep. 2016 Sep 15;4(3):2324709616665408. doi: 10.1177/2324709616665408. eCollection 2016 Jul-Sep. PMID: 27689100 Free PMC Article</br>3:Genetic features of livestock-associated Staphylococcus aureus ST9 isolates from Chinese pigs that carry the lsa(E) gene for quinupristin/dalfopristin resistance. Yan X, Li Z, Chlebowicz MA, Tao X, Ni M, Hu Y, Li Z, Grundmann H, Murray S, Pascoe B, Sheppard SK, Bo X, Dijl JM, Du P, Zhang M, You Y, Yu X, Meng F, Wang S, Zhang J.Int J Med Microbiol. 2016 Dec;306(8):722-729. doi: 10.1016/j.ijmm.2016.08.001. Epub 2016 Aug 10. PMID: 27528592 </br>4:Safety of intravitreal quinupristin/dalfopristin in an animal model. Giordano VE, Hernandez-Da Mota SE, Adabache-Guel TN, Castillejos-Chevez A, Corredor-Casas S, Salinas-Longoria SM, Romero-Vera R, Jimenez-Sierra JM, Guerrero-Naranjo JL, Morales-Canton V.Int J Ophthalmol. 2016 Mar 18;9(3):373-8. doi: 10.18240/ijo.2016.03.08. eCollection 2016. PMID: 27158605 Free PMC Article</br>5:Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital. Maraki S, Samonis G, Dimopoulou D, Mantadakis E.Infect Chemother. 2014 Dec;46(4):253-6. doi: 10.3947/ic.2014.46.4.253. Epub 2014 Dec 29. PMID: 25566405 Free PMC Article</br>6:Emergence of quinupristin/dalfopristin resistance among livestock-associated Staphylococcus aureus ST9 clinical isolates. Yu F, Lu C, Liu Y, Sun H, Shang Y, Ding Y, Li D, Qin Z, Parsons C, Huang X, Li Y, Hu L, Wang L.Int J Antimicrob Agents. 2014 Nov;44(5):416-9. doi: 10.1016/j.ijantimicag.2014.06.020. Epub 2014 Aug 17. PMID: 25218154 </br>7:Antimicrobial susceptibility of Streptococcus sp. to quinupristin-dalfopristin in China. You YH, Wang HB, Tao XX, Song YY, Meng FL, Yan XM, Luo FJ, Zhang JZ.Biomed Environ Sci. 2014 May;27(5):388-90. doi: 10.3967/bes2014.065. PMID: 24827721 Free Article</br>8:Detection of quinupristin-dalfopristin resistance in methicillin-resistant Staphylococcus aureus in South India. Kali A, Stephen S, Umadevi S, Kumar S.Indian J Pathol Microbiol. 2013 Jan-Mar;56(1):73-4. doi: 10.4103/0377-4929.116164. No abstract available. PMID: 23924572 Free Article</br>9:Characterization of Enterococcus faecium with macrolide resistance and reduced susceptibility to quinupristin/dalfopristin in a Japanese hospital: detection of extensive diversity in erm(B)-regulator regions. Isogai N, Urushibara N, Kawaguchiya M, Ghosh S, Suzaki K, Watanabe N, Quiñones D, Kobayashi N.Microb Drug Resist. 2013 Aug;19(4):298-307. doi: 10.1089/mdr.2012.0176. Epub 2013 Feb 26. PMID: 23442208 </br>10:Quinupristin/dalfopristin in vancomycin-resistant Staphylococcus aureus endophthalmitis. Stroh EM.Arch Ophthalmol. 2012 Oct;130(10):1323-4. doi: 10.1001/archophthalmol.2012.1504. No abstract available. PMID: 23044949 |
